Company Short-Term Debt: GTG Labs (GENE)

Public company logo of gtglabs.com (GENE)

The medical sector of Genetic Technologies (GENE) is suffering from logistical disruptions and challenges regarding overseas patent protection. Meanwhile, Genetic Technologies (GENE) is expanding cancer diagnostics through the implementation of new panels. This price chart featuring the 0.00 indicator clearly demonstrates the business dynamics. However, slow recognition of tests by insurance providers and the necessity for new equity offerings create serious financial threats.

GENE (Genetic Technologies) Company Short-Term Debts history from 07/04/2022 to 10/26/2024

Analytical breakdowns and data insights for company Genetic Technologies Ltd (GENE)

- stock price and consensus target price:
Stock Price GTG Labs|GENE - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value Genetic Technologies Limited|GENE - Business Value
- shareholders' equity book value data:
Book Value per Share Genetic Technologies|GENE - Book Capitalization|Market Value to Book Value Ratio gtglabs.com|GENE - Aggregate Company Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Genetic Technologies|GENE - Long-Term Liabilities to Capital|Short-Term Debt to Equity GTG Labs|GENE - Company Total Debt Obligations|Debts to Book Capitalization Genetic Technologies Limited|GENE - Long-Term Debt Volume|Company Short-Term Debt Genetic Technologies|Quick Ratio gtglabs.com
- net income and valuation multiples indicators:
GENE - Annual Net Income
Fundamental company analysis:gtglabs.com (GENE)
Flagship merchandise of GTG Labs

This metric captures the total volume of credit obligations with a maturity of up to one year, allowing for a real-time assessment of the cost of capital without reporting time lags. Monitoring the short-term debt of Genetic Technologies (GENE) as part of portfolio stress testing confirms the stability of Genetic Technologies, whose organic growth strategy and lack of M&A activity minimize the risks of a sharp increase in leverage.

Competitors of Genetic Technologies

Agilent - Company Short-Term Debts|DGX - Company Short-Term Debts|Illumina Corp (ILMN) - Company Short-Term Debt|Company Short-Term Indebtedness EXAS|RVTY (Revvity, Inc.) - Company Short-Term Debts|Company Short-Term Debts bio-rad.com|Company Short-Term Debt Anbio (NNNN)|Company Short-Term Debt SHC (Sotera Health Corp)|QuidelOrtho Corp - Company Current Liabilities|OPKO Health Corp. (OPK) - Short-Term Debt|CDNA - Company Short-Term Debt|Short-Term Debt Volume maravai.com MRVI|FLGT: Company Short-Term Debts|LAB - Short-Term Debt Volume|Company Short-Term Debt Cytek Bio|OraSure Corp (OSUR) - Short-Term Debt Volume|Company Short-Term Debts XGN|mdxhealth.com (MDXH) - Short-Term Indebtedness|Company Short-Term Debts LUCD (Lucid Diagnostics)|Prenetics Global Limited (PRE) - Short-Term Debt|IMDX - Company Short-Term Debt|TRIB (Trinity Biotech plc) - Company Short-Term Indebtedness|PRPH: Company Short-Term Debts|Short-Term Debt ainos.com (AIMD)|Company Current Liabilities CODX|HSCS (Heart Test Laboratories, Inc.) - Amount of Current Liabilities|Company Short-Term Debts BMRA|Short-Term Debt Volume cardiodiagnosticsinc.com|Company Short-Term Debts VRAX (Virax Biolabs Group)|BJDX - Company Current Liabilities|AWH: Company Current Liabilities|Company Short-Term Loans and Borrowings AXDX (Accelerate Diagnostics Inc.)|CNTG (Centogene NV) - Company Current Liabilities|ENZ: Amount of Current Liabilities|FRES (Fresh2 Group Ltd) - Company Short-Term Debts|Short-Term Debt 23andme.com ME|Company Short-Term Debts PMD